Incyte is buying Vega Therapeutics’ subsidiary Star Therapeutics’ Vega unit in a $1.25 billion upfront package, targeting a late-stage von Willebrand disease (VWD) candidate in Phase III development. Under the terms disclosed, Incyte will pay $1.25 billion upfront and may add up to $750 million tied to sales milestones as it builds a longer-term hematology growth platform ahead of product-cycle pressures. The acquisition centers on VGA-039, an investigational monoclonal antibody designed to modulate Protein S to improve hemostasis. Incyte positioned the program as a potential prophylactic option for VWD that could reduce infusion burden through a planned subcutaneous regimen. Key takeaway: the deal is structured to strengthen Incyte’s hematology engine with a near-term registrational asset in a large inherited bleeding population.